- Report
- July 2022
- 40 Pages
Argentina
From €1421EUR$1,500USD£1,200GBP
- Report
- July 2022
- 40 Pages
Poland
From €1421EUR$1,500USD£1,200GBP
From €1421EUR$1,500USD£1,200GBP
- Report
- July 2022
- 40 Pages
United Kingdom
From €1421EUR$1,500USD£1,200GBP
- Report
- July 2022
- 40 Pages
Vietnam
From €1421EUR$1,500USD£1,200GBP
- Report
- July 2022
- 40 Pages
United States
From €1421EUR$1,500USD£1,200GBP
- Report
- July 2022
- 40 Pages
South Korea
From €1421EUR$1,500USD£1,200GBP
- Report
- July 2022
- 40 Pages
Russia
From €1421EUR$1,500USD£1,200GBP
- Report
- July 2022
- 40 Pages
Ireland
From €1421EUR$1,500USD£1,200GBP
- Report
- July 2022
- 40 Pages
Germany
From €1421EUR$1,500USD£1,200GBP
- Report
- July 2022
- 40 Pages
France
From €1421EUR$1,500USD£1,200GBP
- Report
- July 2022
- 40 Pages
Japan
From €1421EUR$1,500USD£1,200GBP
- Report
- May 2022
- 80 Pages
Africa
From €1895EUR$2,000USD£1,599GBP
From €113EUR$119USD£95GBP
- Report
- November 2021
- 747 Pages
Global
From €3790EUR$4,000USD£3,199GBP
- Report
- December 2023
- 248 Pages
Global
From €3383EUR$3,570USD£2,855GBP
- Book
- November 2024
- 464 Pages

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more